Details of the Drug
General Information of Drug (ID: DM0SCDR)
Drug Name |
Piretanide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
piretanide; 55837-27-9; Tauliz; Arlix; 4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid; Piretanido [Spanish]; HOE 118; Piretanidum [INN-Latin]; Piretanido [INN-Spanish]; UNII-DQ6KK6GV93; Arelix (TN); C17H18N2O5S; EINECS 259-852-9; Hoe-118; BRN 5633965; DQ6KK6GV93; 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic acid; 4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid; S 734118; S 73 4118; NCGC00016878-01; 3-(Aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-benzoic acid; Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidin
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 362.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
ADMET Property |
|
||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug Off-Target (DOT) |
|
||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
References